JP2009541223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009541223A5 JP2009541223A5 JP2009515675A JP2009515675A JP2009541223A5 JP 2009541223 A5 JP2009541223 A5 JP 2009541223A5 JP 2009515675 A JP2009515675 A JP 2009515675A JP 2009515675 A JP2009515675 A JP 2009515675A JP 2009541223 A5 JP2009541223 A5 JP 2009541223A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- substituted
- use according
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 19
- 125000000623 heterocyclic group Chemical group 0.000 claims description 19
- 208000032612 Glial tumor Diseases 0.000 claims description 18
- 206010018338 Glioma Diseases 0.000 claims description 18
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 16
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 16
- 125000003107 substituted aryl group Chemical group 0.000 claims description 16
- 206010003571 Astrocytoma Diseases 0.000 claims description 12
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims description 6
- 208000005017 glioblastoma Diseases 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 4
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 125000001475 halogen functional group Chemical group 0.000 claims description 4
- 206010073128 Anaplastic oligodendroglioma Diseases 0.000 claims description 3
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 208000013938 anaplastic oligoastrocytoma Diseases 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 229940035674 anesthetics Drugs 0.000 claims description 2
- 239000003193 general anesthetic agent Substances 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229930014626 natural product Natural products 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 12
- 238000009472 formulation Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 0 *C(C=C(*)N1C2=NC=CC1=O)=C2O Chemical compound *C(C=C(*)N1C2=NC=CC1=O)=C2O 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- -1 derivative Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81577906P | 2006-06-22 | 2006-06-22 | |
| US60/815,779 | 2006-06-22 | ||
| PCT/AU2007/000876 WO2007147217A1 (en) | 2006-06-22 | 2007-06-22 | Method of treatment of glioma brain tumour |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009541223A JP2009541223A (ja) | 2009-11-26 |
| JP2009541223A5 true JP2009541223A5 (enExample) | 2011-02-24 |
| JP5415942B2 JP5415942B2 (ja) | 2014-02-12 |
Family
ID=38833006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009515675A Expired - Fee Related JP5415942B2 (ja) | 2006-06-22 | 2007-06-22 | 処置の方法およびその処置に有用な薬剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8163760B2 (enExample) |
| EP (1) | EP2044026B1 (enExample) |
| JP (1) | JP5415942B2 (enExample) |
| CN (1) | CN101589026B (enExample) |
| AU (1) | AU2007262670B2 (enExample) |
| CA (1) | CA2656825C (enExample) |
| DK (1) | DK2044026T3 (enExample) |
| ES (1) | ES2474865T3 (enExample) |
| WO (1) | WO2007147217A1 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| CN101987849B (zh) * | 2006-04-14 | 2013-05-08 | 普拉纳生物技术有限公司 | 治疗与年龄相关的黄斑变性(amd)的方法 |
| JP5419706B2 (ja) * | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| US9321730B2 (en) * | 2007-08-21 | 2016-04-26 | The Hong Kong Polytechnic University | Method of making and administering quinoline derivatives as anti-cancer agents |
| US8071766B2 (en) | 2008-02-01 | 2011-12-06 | Takeda Pharmaceutical Company Limited | HSP90 inhibitors |
| GB0806794D0 (en) * | 2008-04-15 | 2008-05-14 | Ludwig Inst Cancer Res | Therapeutic compounds |
| US9284297B2 (en) * | 2008-08-11 | 2016-03-15 | President And Fellows Of Harvard College | Halofuginone analogs for inhibition of tRNA synthetases and uses thereof |
| ES2634492T3 (es) | 2008-12-24 | 2017-09-28 | Prana Biotechnology Ltd | Compuestos de quinazolinona |
| US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| WO2012083866A1 (en) | 2010-12-22 | 2012-06-28 | The Hong Kong Polytechnic University | Quinoline derivatives as anti-cancer agents |
| EP2565186A1 (en) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| FR2984317B1 (fr) * | 2011-12-20 | 2015-02-27 | Univ Rennes | Composes chelateurs de metal presentant au moins une chaine polyaminee. |
| CA2861840C (en) | 2012-01-13 | 2020-12-15 | President And Fellows Of Harvard College | Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions |
| PH12019502809B1 (en) | 2012-06-13 | 2024-04-24 | Incyte Holdings Corp | Substituted tricyclic compounds as fgfr inhibitors |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| JP6027267B2 (ja) * | 2012-12-27 | 2016-11-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｃｏｍｔ阻害剤 |
| EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| MY181497A (en) | 2013-04-19 | 2020-12-23 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| TW201605805A (zh) * | 2013-10-23 | 2016-02-16 | Chugai Pharmaceutical Co Ltd | 喹唑啉酮及異喹啉酮衍生物 |
| EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| JP6784942B2 (ja) * | 2014-12-02 | 2020-11-18 | オールテリティ セラピューティクス リミテッド | ４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オン化合物 |
| PE20171514A1 (es) | 2015-02-20 | 2017-10-20 | Incyte Corp | Heterociclos biciclicos como inhibidores de fgfr |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| WO2019067503A1 (en) | 2017-09-26 | 2019-04-04 | Dana-Farber Cancer Institute, Inc. | NEW USP7 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA |
| CN112867716B (zh) | 2018-05-04 | 2024-09-13 | 因赛特公司 | Fgfr抑制剂的固体形式和其制备方法 |
| JP7568512B2 (ja) | 2018-05-04 | 2024-10-16 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の塩 |
| WO2019237125A1 (en) | 2018-06-08 | 2019-12-12 | The General Hospital Corporation | Inhibitors of prolyl-trna-synthetase |
| WO2020086595A1 (en) | 2018-10-22 | 2020-04-30 | Dana-Farber Cancer Institute, Inc. | Usp7 inhibition |
| EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
| CN111471012B (zh) * | 2019-01-23 | 2023-04-25 | 鲁南制药集团股份有限公司 | 一种蜈蚣喹啉类化合物、制备方法及其应用 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN110240590B (zh) * | 2019-07-16 | 2025-09-19 | 广州新民培林医药科技有限公司 | 一类嘧啶喹啉衍生物及其制备方法和应用 |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| AU2020394867A1 (en) | 2019-12-02 | 2022-05-26 | Storm Therapeutics Limited | Polyheterocyclic compounds as METTL3 inhibitors |
| WO2021113462A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| ES3035284T3 (en) | 2020-07-02 | 2025-09-01 | Incyte Corp | Tricyclic urea compounds as jak2 v617f inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| CA3211748A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| CA3215903A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CN113214249B (zh) * | 2021-04-23 | 2023-09-19 | 成都大学 | 吡啶并[1,2-a]嘧啶-4-硫酮化合物的合成方法 |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| JP2024522188A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| EP4653053A1 (en) | 2021-11-02 | 2025-11-26 | Flare Therapeutics, Inc. | Pparg inverse agonists and uses thereof |
| PE20251706A1 (es) | 2022-03-17 | 2025-07-02 | Incyte Corp | Compuestos de urea triciclica como inhibidores de v617f de jak2 |
| CN116410132B (zh) * | 2023-02-23 | 2024-07-09 | 广东工业大学 | 一种8-羟基喹啉类化合物及其制备方法和在制备抗肿瘤药物上的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL145401A0 (en) * | 1999-03-24 | 2002-06-30 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
| AU2001230426C1 (en) * | 2000-01-24 | 2006-06-22 | Astrazeneca Ab | Therapeutic morpholino-substituted compounds |
| WO2002060373A2 (en) * | 2001-01-29 | 2002-08-08 | Insight Strategy And Marketing Ltd | Indole derivatives and their uses as heparanase inhibitors |
| IL159086A0 (en) * | 2001-06-08 | 2004-05-12 | Cytovia Inc | 3-aryl-5-aryl- [1, 2, 4] -oxadiazole derivatives and pharmaceutical compositions containing the same |
| BR0307874A (pt) * | 2002-02-20 | 2004-12-28 | Upjohn Co | Atividade de compostos azabicìclicos com receptor de acetilcolina nicotìnica alfa7 |
| HK1079789A1 (zh) | 2002-10-03 | 2006-04-13 | Targegen, Inc. | 血管静态毒性试剂及其使用方法 |
| US7692011B2 (en) * | 2002-10-04 | 2010-04-06 | Prana Biotechnology Limited | 8-hydroxy and 8-mercapto quinazolinones |
| WO2005063213A1 (en) * | 2003-12-19 | 2005-07-14 | Biodelivery Sciences International, Inc. | Rigid liposomal cochleate and methods of use and manufacture |
| US20060100226A1 (en) | 2004-09-10 | 2006-05-11 | Sikorski James A | 2-Thiopyrimidinones as therapeutic agents |
| BRPI0619252A2 (pt) | 2005-11-30 | 2011-09-20 | Vertex Pharma | inibidores de c-met e seus usos |
| DE102005059479A1 (de) * | 2005-12-13 | 2007-06-14 | Merck Patent Gmbh | Hydroxychinolinderivate |
| CN101987849B (zh) * | 2006-04-14 | 2013-05-08 | 普拉纳生物技术有限公司 | 治疗与年龄相关的黄斑变性(amd)的方法 |
-
2007
- 2007-06-22 AU AU2007262670A patent/AU2007262670B2/en not_active Ceased
- 2007-06-22 ES ES07719115.3T patent/ES2474865T3/es active Active
- 2007-06-22 US US12/306,202 patent/US8163760B2/en not_active Expired - Fee Related
- 2007-06-22 EP EP07719115.3A patent/EP2044026B1/en not_active Not-in-force
- 2007-06-22 DK DK07719115.3T patent/DK2044026T3/da active
- 2007-06-22 JP JP2009515675A patent/JP5415942B2/ja not_active Expired - Fee Related
- 2007-06-22 WO PCT/AU2007/000876 patent/WO2007147217A1/en not_active Ceased
- 2007-06-22 CA CA2656825A patent/CA2656825C/en not_active Expired - Fee Related
- 2007-06-22 CN CN2007800311672A patent/CN101589026B/zh not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009541223A5 (enExample) | ||
| JP5931982B2 (ja) | （ａ）ホスホイノシタイド３−キナーゼ阻害剤および（ｂ）Ｒａｓ／Ｒａｆ／Ｍｅｋ経路のモジュレーターの配合物 | |
| RU2448096C2 (ru) | Диарилгидантоины | |
| JP2016513661A5 (enExample) | ||
| US20160287605A1 (en) | Combination therapy | |
| US20090054415A1 (en) | Combinations, methods and compositions for treating cancer | |
| CN105163584A (zh) | 用于治疗癌症的化合物 | |
| JP2008535902A5 (enExample) | ||
| KR20180054657A (ko) | Dna 손상제 및 atr 저해제의 병용물을 사용한 암 치료 방법 | |
| TN2013000293A1 (en) | Derivatives of azaindazole or diazaindazole type as medicament | |
| MX2023014630A (es) | Activadores de dimetoxifenilalquilamina de receptores de serotonina. | |
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| RU2007110629A (ru) | Ингибиторы днк-пк | |
| KR20160126984A (ko) | 아필리모드 조성물 및 이를 사용하기 위한 방법 | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| EA201991025A1 (ru) | Липосомальный препарат для применения для лечения злокачественного новообразования | |
| WO2014106800A8 (en) | Substituted 2-amino pyrimidine derivatives as kinase inhibitors | |
| ECSP099767A (es) | Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas | |
| AU2014280354A1 (en) | Combinations for the treatment of cancer comprising a Mps-1 kinase inhibitor and a mitotic inhibitor | |
| BR112012022632A2 (pt) | Medicamento compreendendo agonista de ep4 | |
| WO2007059155A1 (en) | Treatment of cancers having resistance to chemotherapeutic agents | |
| JP2017515857A5 (enExample) | ||
| RU2011139157A (ru) | Производное трициклического пиразолопиримидина | |
| US6355628B1 (en) | Combination therapy using pentafluorobenzenesulfonamides | |
| JP2019516726A5 (enExample) |